Investing in tomorrow's healthcare

CamBioScience Ltd has secured c.£1.1m of funding led by an early stage investment house, Beaubridge (UK) Ltd

 

 

CamBioScience Ltd, an emerging force in advanced training and machine learning systems, has secured c.£1.1m of funding led by an early stage investment house, Beaubridge (UK) Ltd. This investment will fuel the global scale-up of OBRIZUM®, a transformative learning platform that incorporates artificial intelligence (AI) to maximize and quicken individual employee learning and training processes—ultimately enhancing their company’s operations and development. OBRIZUM® leverages powerful AI algorithms to continually personalise and enhance each employee’s learning experience. It also automates data organisation and transfer and generates deep, real-time analytical reports that quantify a company’s return on learning investment for businesses.

 

Businesses face an unrelenting challenge when it comes to employee empowerment via learning and training. They must evolve and maximize their processes or face extinction. “OBRIZUM transforms E-Learning into AI-Learning and takes personalised learning to another level. This latest financing from Beaubridge will help us realize OBRIZUM’s full global potential and bring powerful learning and training benefits to business and individuals alike—just when they need it most,” said Chibeza C. Agley, PhD, Chief Executive Officer, CamBioScience.

 

Beaubridge (UK) Ltd is a London based FCA authorised firm. It is independently owned and focuses on early stage UK businesses. It is sector agnostic and to date has concentrated on financial services, aesthetics and education. “Beaubridge is very excited to be working with the extremely talented and driven CamBioScience team. We are confident that OBRIZUM's unique AI enhanced E-Learning platform will transform corporate education and disrupt the wider education market” said Derk Ohler, Investment Director, Beaubridge (UK) Ltd. who is joining CamBioScience Ltd.’s board of directors “This is an exciting time to be investing in Ed-Tech and CamBioScience is at the forefront of this industry.” In leading the round, Beaubridge (UK) Ltd. joins an investor base that includes Cambridge Capital Group, Angels in MedCity, Henley’s Business Angels, and private investors from the UK, Dubai, and Germany.

 

CamBioScience’s leading AI specialists have built OBRIZUM® to make this transformation a reality by specifically addressing the three greatest challenges confronting digital learning.

 

About CamBioScience

CamBioScience Ltd. is based in Cambridge, UK. An emerging force in the field of artificial intelligence (AI) and machine-based learning, it brings together cutting-edge technologists, leading academics, software developers and business visionaries to make deep data more user friendly; offer advanced life science training courses; and develop AI learning platforms that help transform the way people and businesses operate. To learn more, please visit www.cambioscience.com or www.obrizum.com

 

About Beaubridge (UK) Ltd

Beaubridge (UK) Ltd is a London based FCA authorised firm. It is independently owned and focuses on early stage UK businesses. It is sector agnostic and to date has concentrated on financial services, aesthetics and education. To learn more, please visit www.beaubridge.com

 

Monday, January 7, 2019 - 11:30

Become an Angels in MedCity investor

Become an investor >

 

Become an Angels in MedCity entrepreneur

Entrepreneurs >

 

On Twitter

#Diversity is important in teams. Different perspectives and experiences can only enrich the management and decisio… https://t.co/z5QZgShDUg
23 hours 1 sec ago
Check out the e attributes of an #InvestedInvestor! For early ventures smart money is key! https://t.co/n0g6IpEX19
4 days 1 hour ago